Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
Chinese researchers:
GZNL-P36 is a promising drug candidate for COVID-19 targeting a conserved viral enzyme, showing broad antiviral and anti-inflammatory effects.
Mouse trials: it reduces viral load, inflammation, and lung damage